An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Celebrities like Matthew Perry, Chrissy Teigen and others have been open about using ketamine infusion therapy to help treat ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

While ketamine is celebrated as a breakthrough depression treatment, new research highlights a significant rise in its ...

Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

This can then be followed by a dexmedetomidine infusion (1–2 μg/kg/hr) with supplemental bolus doses of ketamine (0.5–1 mg/kg) as needed. Conclusions: The available literature except for one ...

New research involving ketamine continues show that having a mystical experience is key to the effectiveness of psychedelic ...